CardioNet, Inc. Appoints Michael Geldart Senior Vice President, Corporate Strategy and Business Development
June 20 2012 - 4:05PM
Business Wire
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical
technology company with an initial focus on the diagnosis and
monitoring of cardiac arrhythmias, announced today the appointment
of Michael Geldart as Senior Vice President, Corporate Strategy and
Business Development.
Mr. Geldart has over 20 years of experience in executive
management in healthcare and consulting. He recently served as
Chief Operating Officer for MedExpress Urgent Care, one of the
largest urgent care providers in the country. Previous to that, Mr.
Geldart served as Executive Vice President of Corporate Development
and Integration with CCS Medical Inc. in Clearwater, FL, where he
helped grow annual revenues from $60 million to over $500 million
in five years. His other roles at CCS included Chief Operating
Officer, General Counsel, and Chief Compliance Officer. Prior to
CCS, Mr. Geldart spent thirteen years in private practice with
Holland & Knight, a global law firm, and was a Partner and
co-chair of the national health law practice group. He holds a law
degree from Stetson University, where he also spent time as an
adjunct professor.
Joseph H. Capper, President and Chief Executive Officer of
CardioNet, commented, “We are pleased to welcome Mike to the
CardioNet executive team. He is a strategic-minded,
results-oriented leader with an entrepreneurial mindset. In this
critical new role, Mike will work with the team to further develop
and execute our strategic plan to grow and diversify our core
business in order to create additional sources of revenue. This is
another significant step in the furtherance of our previously
announced plan to leverage our existing infrastructure and expand
into adjacent markets.”
About CardioNet
CardioNet is the leading provider of ambulatory, continuous,
real-time outpatient management solutions for monitoring relevant
and timely clinical information regarding an individual’s health.
CardioNet’s initial efforts are focused on the diagnosis and
monitoring of cardiac arrhythmias, or heart rhythm disorders, with
a solution that it markets as Mobile Cardiac Outpatient Telemetry™
(MCOT™). More information can be found at
http://www.cardionet.com.
Forward-Looking Statements
This document includes certain forward-looking statements within
the meaning of the “Safe Harbor” provisions of the Private
Securities Litigation Reform Act of 1995 regarding, among other
things, our growth prospects, the prospects for our products and
our confidence in the Company’s future. These statements may be
identified by words such as “expect,” “may,” “anticipate,”
“possible,” “estimate,” “potential,” “intend,” “plan,” “believe,”
“forecast,” “promises” and other words and terms of similar
meaning. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any
of them, and could cause actual outcomes and results to differ
materially from current expectations. For further details and a
discussion of these and other risks and uncertainties, please see
our public filings with the Securities and Exchange Commission,
including our latest periodic reports on Form 10-K and 10-Q. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024